CMF
AMED

Counterpoint Mutual Funds’s Amedisys AMED Stock Holding History

Counterpoint Mutual Funds’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,286
Closed -$107K – 337
2022
Q4 		$107K Buy
+1,286
New +$116K 0.11% 238

Other funds holding AMED

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Counterpoint Mutual Funds's AMED Position: Q1 2023 in Review

Counterpoint Mutual Funds sold out of Amedisys (AMED) in Q1 2023, closing a stake of 1,286 shares — an estimated $107K sold.

Counterpoint Mutual Funds first reported a position in AMED in Q4 2022 and held it in 1 quarter. The position peaked at $107K in Q4 2022. 281 funds tracked by Wall St. Rank hold AMED as of Q1 2023.

  • Counterpoint Mutual Funds reported no remaining Amedisys position as of Q1 2023 after selling out during the quarter.
  • Counterpoint Mutual Funds sold 1,286 Amedisys shares in Q1 2023, an estimated $107K.
  • Counterpoint Mutual Funds first reported a position in Amedisys in Q4 2022 and held it in 1 quarter.
  • Counterpoint Mutual Funds's Amedisys position peaked at $107K in Q4 2022.
  • 281 funds tracked by Wall St. Rank held Amedisys as of Q1 2023.

Based on Counterpoint Mutual Funds's 13F filing for Q1 2023, filed 20 Apr 2023.